Experimental
Crystal data Table 1 Hydrogen-bond geometry (Å , ). Data collection: COLLECT (Nonius, 1998); cell refinement: DENZO and SCALEPACK (Otwinowski & Minor, 1997) ; data reduction: DENZO and SCALEPACK; program(s) used to solve structure: SHELXS97 (Sheldrick, 2008); program(s) used to refine structure: SHELXL97 (Sheldrick, 2008); molecular graphics: ORTEP-3 for Windows (Farrugia, 2012) ; software used to prepare material for publication: SHELXL97 and PLATON (Spek, 2009 There has been an intense interest in the preparation and characterization of pharmaceutical cocrystals which is evident from the increasing number of research publications on this topic in the past decade (Brittain, 2012a,b and references therein) . Pharmaceutical cocrystals present a sub-set of multicomponent crystal solid forms of the active pharmaceutical ingredient (API) with the ability to modulate API's physicochemical properties and to provide intellectual property implications. Until now no cocrystal drug substances have received regulatory approval yet. The relevance of cocrystals in drug formulation research and development has been confirmed with the publication of new U.S. Food and Drug Administration's (FDA) draft guidance for the regulatory classification of pharmaceutical cocrystals in December 2011 (US Food and Drug Administration, 2011) .
Fluconazole is a wide spectrum triazole antifungal agent which is only slightly soluble in water. It is a weak base (pK a value of 1.76 for its conjugated acid). Therefore, the formation of a salt as a mean to improve solubility properties, could only be expected with very strong acids. On the other hand, cocrystallization offers possibilities to influence the solubility with numerous coformers. Along these lines, we have focused our research on the preparation of new fluconazole cocrystals. The results of our systematic cocrystallization screening are the cocrystals of fluconazole with three dicarboxylic acids, namely maleic, glutaric and fumaric (Kastelic et al., 2010) and a cocrystal with salicylic acid (Kastelic et al., 2011) . As a continuation of our work we present here the crystal structure of a 1:1 cocrystal of fluconazole with malonic acid.
The asymmetric unit consists of one fluconazole and one malonic acid molecule, both in their neutral forms (Fig. 1 ).
Both crystal formers can act as donors and/or acceptors in hydrogen bonding. As expected, the packing arrangement of the two molecules in the crystal is governed by hydrogen-bond interactions. A basic packing motif may be envisioned as a ring in which two fluconazole molecules (related by a two fold axis; symmetry code: +1-x, y, +1.5-z) are bridged by two malonic acid molecules by hydrogen bond interactions including fluconazole OH group as a donor to carboxylic O atom of malonic acid (for hydrgen bond geometry see Table 1 ). Additionally, the same carboxylic group acts as a donor to one of the triazole N atoms of the fluconazole moiety (Fig. 2) . Such rings are further connected into two-dimensional layers through the interaction of the second carboxylic group of malonic acid with another fluconazole triazole nitrogen atom (N24) of the adjacent building unit . The layers are oriented perpendicular to the z axis (Fig. 3) . Additionally, the structure is stabilized by non-classical H-bond interactions (for details see Table 1 ). 
Fluconazole was obtained from Krka d.d., Novo mesto, malonic acid was obtained from Merck and both were used without further purification. Equimolar amounts of fluconazole (100 mg, 0.33 mmol) and malonic acid (34.3 mg, 0.33 mmol) were dissolved in 3 ml of acetonitrile by heating at 50°C. The clear solution was slowly cooled to ambient temperature and solvent was then allowed to evaporate to form a transparent film from which crystals grew in 72 h.
Crystals suitable for single-crystal X-ray diffraction analysis were prepared by dissolving fluconazole (100.0 mg, 0.33 mmol) and malonic acid (34.3 mg, 0.33 mmol) in 3 ml of acetonitrile by heating at 50°C. Seeds from screening experiment described above were added to clear solution. The mixture was slowly cooled to ambient temperature and allowed to evaporate slowly until the crystals of suitable size and quality appeared.
Refinement
All H atoms were initially found in a Fourier-difference map, but they were repositioned to their calculated positions and were refined using a riding model. Aromatic H atoms were permitted to ride with C-H = 0.93 Å and U eq (H) = 1.2U iso (C). H atoms of the CH 2 group were constrained with C-H = 0.97 Å and U eq (H)=1.2U iso (C). H atoms of hydroxyl groups involved in the formation of hydrogen bonds were freely refined.
Computing details
Data collection: COLLECT (Nonius, 1998); cell refinement: DENZO and SCALEPACK (Otwinowski & Minor, 1997 are statistically about twice as large as those based on F, and R-factors based on ALL data will be even larger. Symmetry codes: (i) −x+1, y, −z+3/2; (ii) −x+1/2, y−1/2, z; (iii) −x+1/2, y+1/2, z; (iv) x+1/2, y−1/2, −z+3/2.
Fractional atomic coordinates and isotropic or equivalent isotropic displacement parameters (

